Richard W Joseph1, Gurkamal Chatta2, Ulka Vaishampayan3. 1. Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL. Electronic address: joseph.richard@mayo.edu. 2. Clinical Chief for Genitourinary Medicine, Professor of Oncology, Roswell Park Cancer Institute, Buffalo, NY. 3. Professor of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI.
Abstract
BACKGROUND: Nivolumab is an important new therapy option for patients with advanced renal cell carcinoma, and has a different mechanism of action compared with vascular endothelial growth factor -targeted therapies. It is a programmed death 1 immune checkpoint inhibitor antibody with response patterns, efficacy, and safety profiles that differ from those of conventional antiangiogenic or mammalian target of rapamycin inhibition therapy. METHODS AND PURPOSE: This commentary discusses and evaluates the clinical experience with nivolumab from the available literature and presents practical considerations for the use of nivolumab immunotherapy in aRCC to optimize clinical management.
BACKGROUND:Nivolumab is an important new therapy option for patients with advanced renal cell carcinoma, and has a different mechanism of action compared with vascular endothelial growth factor -targeted therapies. It is a programmed death 1 immune checkpoint inhibitor antibody with response patterns, efficacy, and safety profiles that differ from those of conventional antiangiogenic or mammalian target of rapamycin inhibition therapy. METHODS AND PURPOSE: This commentary discusses and evaluates the clinical experience with nivolumab from the available literature and presents practical considerations for the use of nivolumab immunotherapy in aRCC to optimize clinical management.
Authors: Toni K Choueiri; Bernard Escudier; Thomas Powles; Paul N Mainwaring; Brian I Rini; Frede Donskov; Hans Hammers; Thomas E Hutson; Jae-Lyun Lee; Katriina Peltola; Bruce J Roth; Georg A Bjarnason; Lajos Géczi; Bhumsuk Keam; Pablo Maroto; Daniel Y C Heng; Manuela Schmidinger; Philip W Kantoff; Anne Borgman-Hagey; Colin Hessel; Christian Scheffold; Gisela M Schwab; Nizar M Tannir; Robert J Motzer Journal: N Engl J Med Date: 2015-09-25 Impact factor: 91.245
Authors: Lowell E Schnipper; Nancy E Davidson; Dana S Wollins; Douglas W Blayney; Adam P Dicker; Patricia A Ganz; J Russell Hoverman; Robert Langdon; Gary H Lyman; Neal J Meropol; Therese Mulvey; Lee Newcomer; Jeffrey Peppercorn; Blase Polite; Derek Raghavan; Gregory Rossi; Leonard Saltz; Deborah Schrag; Thomas J Smith; Peter P Yu; Clifford A Hudis; Julie M Vose; Richard L Schilsky Journal: J Clin Oncol Date: 2016-05-31 Impact factor: 44.544
Authors: R Houston Thompson; Michael D Gillett; John C Cheville; Christine M Lohse; Haidong Dong; W Scott Webster; Kent G Krejci; John R Lobo; Shomik Sengupta; Lieping Chen; Horst Zincke; Michael L Blute; Scott E Strome; Bradley C Leibovich; Eugene D Kwon Journal: Proc Natl Acad Sci U S A Date: 2004-11-29 Impact factor: 11.205
Authors: Thomas E Hutson; Bernard Escudier; Emilio Esteban; Georg A Bjarnason; Ho Yeong Lim; Kenneth B Pittman; Peggy Senico; Andreas Niethammer; Dongrui Ray Lu; Subramanian Hariharan; Robert J Motzer Journal: J Clin Oncol Date: 2013-12-02 Impact factor: 44.544
Authors: Robert J Motzer; Bernard Escudier; Piotr Tomczak; Thomas E Hutson; M Dror Michaelson; Sylvie Negrier; Stephane Oudard; Martin E Gore; Jamal Tarazi; Subramanian Hariharan; Connie Chen; Brad Rosbrook; Sinil Kim; Brian I Rini Journal: Lancet Oncol Date: 2013-04-16 Impact factor: 41.316
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: Robert J Motzer; Bernard Escudier; David F McDermott; Saby George; Hans J Hammers; Sandhya Srinivas; Scott S Tykodi; Jeffrey A Sosman; Giuseppe Procopio; Elizabeth R Plimack; Daniel Castellano; Toni K Choueiri; Howard Gurney; Frede Donskov; Petri Bono; John Wagstaff; Thomas C Gauler; Takeshi Ueda; Yoshihiko Tomita; Fabio A Schutz; Christian Kollmannsberger; James Larkin; Alain Ravaud; Jason S Simon; Li-An Xu; Ian M Waxman; Padmanee Sharma Journal: N Engl J Med Date: 2015-09-25 Impact factor: 91.245
Authors: R Houston Thompson; Haidong Dong; Christine M Lohse; Bradley C Leibovich; Michael L Blute; John C Cheville; Eugene D Kwon Journal: Clin Cancer Res Date: 2007-03-15 Impact factor: 12.531
Authors: Joshua D Ochocki; Sanika Khare; Markus Hess; Daniel Ackerman; Bo Qiu; Jennie I Daisak; Andrew J Worth; Nan Lin; Pearl Lee; Hong Xie; Bo Li; Bradley Wubbenhorst; Tobi G Maguire; Katherine L Nathanson; James C Alwine; Ian A Blair; Itzhak Nissim; Brian Keith; M Celeste Simon Journal: Cell Metab Date: 2018-05-10 Impact factor: 27.287
Authors: Stéphane Chevrier; Jacob Harrison Levine; Vito Riccardo Tomaso Zanotelli; Karina Silina; Daniel Schulz; Marina Bacac; Carola Hermine Ries; Laurie Ailles; Michael Alexander Spencer Jewett; Holger Moch; Maries van den Broek; Christian Beisel; Michael Beda Stadler; Craig Gedye; Bernhard Reis; Dana Pe'er; Bernd Bodenmiller Journal: Cell Date: 2017-05-04 Impact factor: 41.582